Search Results - "Terrisse, S.A."

Response to chemotherapy is not related to chromosome instability in synovial sarcoma by Chakiba, C., Lagarde, P., Pissaloux, D., Neuville, A., Brulard, C., Pérot, G., Coindre, J.M., Terrier, P., Ranchere-Vince, D., Ferrari, A., Collini, P., Suurmeijer, A.J.H., Blay, J.Y., Terrisse, S.A., Piperno-Neumann, S., Averous, G., Bui, B., Orbach, D., Italiano, A., Chibon, F.

“…Synovial sarcoma (SS) is an aggressive soft-tissue tumor. Despite being considered as a chemosensitive disease, the real impact of perioperative chemotherapy…”
Get full text

Early Psa Response is an Independent Prognostic Factor in Patients with Mcrpc Treated with Next-Generation Androgen Pathway Inhibitors by Fuerea, A.C., Baciarello, G., Massard, C., Sauvin, L. Albiges, Gizzi, M., Terrisse, S.A., Di Palma, M., Escudier, B., Fizazi, K., Loriot, Y.

Get full text

796PEARLY PSA RESPONSE IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH MCRPC TREATED WITH NEXT-GENERATION ANDROGEN PATHWAY INHIBITORS by Fuerea, A.C., Baciarello, G., Massard, C., Sauvin, L. Albiges, Gizzi, M., Terrisse, S.A., Di Palma, M., Escudier, B., Fizazi, K., Loriot, Y.

“…Abstract Aim: To determine the clinical significance of early PSA response during the first 4 weeks of therapy with next-generation androgen pathway inhibitors…”
Get full text